{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:09:10Z","timestamp":1781359750269,"version":"3.54.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Introduction. Bisphosphonates (BPs) delay the onset or reduce the incidence of skeletal complications in patients with bone metastases. However, there are few data on the renal safety and activity of i.v. BPs beyond 2 years of administration.<\/jats:p>\n               <jats:p>Materials and Methods. We retrospectively analyzed serum creatinine (SCr) levels and skeletal-related events (SREs) in cancer patients receiving i.v. BPs for \u2265 24 months. All patients received 90 mg pamidronate every 3\u20134 weeks. Pre- and post-treatment SCr levels and the peak levels attained were recorded. A notable SCr increase was defined as: an increase &amp;gt;0.5 mg\/dl for patients with baseline SCr &amp;lt;1.4 mg\/dl; an increase &amp;gt;1 mg\/dl for patients with baseline SCr &amp;gt;1.4 mg\/dl; or doubling over baseline. The following parameters were also analyzed: the proportion of patients with at least one SRE, the distribution of each type of SRE, the time to first SRE, and the skeletal morbidity rate (SMR).<\/jats:p>\n               <jats:p>Results. Fifty-seven patients with bone metastases resulting from breast cancer (BC) (n = 48), multiple myeloma (n = 7), renal cell carcinoma (n = 1), and prostate cancer (n = 1) were evaluated. The median age at the start of treatment was 57 years (range, 27\u201381); 25% of the patients were &amp;gt;70 years old. Forty-three patients received pamidronate then switched to zoledronic acid. The median overall duration of BP administration was 34 months (range, 24+ to 131+), with a median duration of zoledronic acid therapy of 25 months (range, 2\u201340). Twenty-seven of 48 BC patients received different chemotherapy regimens (median number of lines, 2; range, 1\u20136). The median SCr levels were: baseline, 0.82 mg\/dl (range, 0.4\u20131.4); time of analysis, 0.89 mg\/dl (0.4\u20132); highest level, 1.0 mg\/dl (0.5\u20132). A notable SCr increase was observed in seven patients (12.2%; all grade 1). Twenty-six patients (45.6%) experienced SREs after starting BP treatment. The median time to first SRE was 911 days (95% confidence interval, 731; 1,023). The SMR was 0.20 events per year. Ten patients ceased treatment because of: an SCr level of 2 mg\/dl (n = 1) physician decision (n = 6) and jaw osteonecrosis (n = 3). Ten patients died of progressive disease.<\/jats:p>\n               <jats:p>Conclusion. i.v. BPs are safe and active during prolonged treatment administration, and renal function is maintained in patients receiving multiple cytotoxic therapies. Jaw osteonecrosis occurred in 5% of the study population, and its causal relationship with BP treatment requires further observation and study.<\/jats:p>","DOI":"10.1634\/theoncologist.10-10-842","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T22:43:54Z","timestamp":1132785834000},"page":"842-848","source":"Crossref","is-referenced-by-count":69,"title":["Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years"],"prefix":"10.1093","volume":"10","author":[{"given":"Valentina","family":"Guarneri","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Donati","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, St. Chiara University Hospital, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Giovannelli","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D'Amico","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Franco","family":"Conte","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,11,1]]},"reference":[{"key":"2021122209515791000_R1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"2021122209515791000_R2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"2021122209515791000_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"key":"2021122209515791000_R4","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2021122209515791000_R5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminoncol.2003.08.017","article-title":"Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors","volume":"30","author":"Lacerna","year":"2003","journal-title":"Semin Oncol"},{"key":"2021122209515791000_R6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","article-title":"Comparative tolerability of drug therapies for hypercalcaemia of malignancy","volume":"21","author":"Zojer","year":"1999","journal-title":"Drug Saf"},{"key":"2021122209515791000_R7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","article-title":"Renal failure associated with intravenous diphosphonates","volume":"1","author":"Bounameaux","year":"1983","journal-title":"Lancet"},{"key":"2021122209515791000_R8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0169-6009(91)90131-I","article-title":"Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia","volume":"15","author":"Dumon","year":"1991","journal-title":"Bone Miner"},{"key":"2021122209515791000_R9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2021122209515791000_R10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"2021122209515791000_R11","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/ndt\/12.12.2797","article-title":"Acute renal failure and alendronate","volume":"12","author":"Zazgornik","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"2021122209515791000_R12","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0272-6386(03)00214-2","article-title":"Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity","volume":"41","author":"Banerjee","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2021122209515791000_R13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1523-1755.2004.00426.x","article-title":"Podocyte injury associated glomerulopathies induced by pamidronate","volume":"65","author":"Barri","year":"2004","journal-title":"Kidney Int"},{"key":"2021122209515791000_R14","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"2021122209515791000_R15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122209515791000_R16","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"2021122209515791000_R17","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209515791000_R18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122209515791000_R19","first-page":"S75","article-title":"Ibandronate does not affect time to renal function deterioration over 2 years of treatment: phase III trials","volume":"34","author":"Bell","year":"2004","journal-title":"Bone"},{"key":"2021122209515791000_R20","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1200\/JCO.2001.19.14.3434","article-title":"Safety and efficacy of bisphosphonates beyond 24 months in cancer patients","volume":"19","author":"Ali","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209515791000_R21","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2005.11.931","article-title":"Progress in the management of bone metastases: one continent at a time?","volume":"23","author":"Hortobagyi","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209515791000_R22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122209515791000_R23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021122209515791000_R24","first-page":"S101","article-title":"Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat","volume":"49","author":"Kapitola","year":"2000","journal-title":"Physiol Res"},{"key":"2021122209515791000_R25","first-page":"237","article-title":"Effect of pamidronate on blood flow in oophorectomized rats","volume":"47","author":"Kapitola","year":"1998","journal-title":"Physiol Res"},{"key":"2021122209515791000_R26","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"2021122209515791000_R27","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","article-title":"Osteonecrosis of the jaws associated with cancer chemotherapy","volume":"61","author":"Wang","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"2021122209515791000_R28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122209515791000_R29","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.joms.2003.09.001","article-title":"Avascular necrosis of the jaws: risk factors in metastatic cancer patients","volume":"61","author":"Tarassoff","year":"2003","journal-title":"J Oral Maxillofac Surg"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.10-10-842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.10-10-842","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/10\/10\/842\/41852338\/oncolo_10_10_842.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/10\/10\/842\/41852338\/oncolo_10_10_842.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:44:34Z","timestamp":1640195074000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/10\/10\/842\/6387363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,11,1]]},"published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.10-10-842","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,11,1]]},"published":{"date-parts":[[2005,11,1]]}}}